{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-25-000132","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.981237+00:00","generated_at":"2026-05-16T23:43:12.620750+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolent Q3 Adj EBITDA $39M (8.1% margin); new CFO Ramos; 2026 revenue forecast $2.5B","bullets":["Q3 revenue $479.5M, net loss $26.9M; adjusted EBITDA $39.0M vs $31.8M YoY.","Two new customer agreements bring YTD total to 13; >$750M new annualized revenue to launch in 2026.","Mario Ramos appointed CFO effective Jan 1, 2026; John Johnson becomes Chief Strategy Officer.","New CFO Ramos receives $550K base salary, $625K bonus, $100K sign-on bonus, and $2.35M RSU grant.","Katie DiPerna named COO; Emily Rafferty transitions to EVP Customer Success."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-25-000132","json":"https://secwatch.observer/filing/0001628908-25-000132.json","markdown":"https://secwatch.observer/filing/0001628908-25-000132.md","text":"https://secwatch.observer/filing/0001628908-25-000132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890825000132/0001628908-25-000132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890825000132/evh-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:43:12.620750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}